CME
Latest Episodes
Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?
Host: Ritu Salani, MD, MBA This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants wi
Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors
Host: Shubham Pant, MD, MBBS This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants
Patient Case: How Do HER2-Directed Therapies Fit Into the Ovarian Cancer Treatment Landscape?
Host: Ritu Salani, MD, MBA This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants wi
Significance of HER2 Expression in Solid Tumors
Host: Shubham Pant, MD, MBBS Host: Ritu Salani, MD, MBA This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical
Frontline Fixed-Duration Therapy in CLL: Improving Outcomes and Tolerability
Host: Thomas Kipps, MD, PhD Host: William Wierda, MD, PhD Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, p
Fixed-Duration vs Continuous-Dosing Approaches in CLL: Impact on QoL and Toxicity Risk
Host: William Wierda, MD, PhD Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisti
The Challenge of BCL-2 Resistance in CLL: Treatment Strategies and Emerging Therapies
Host: Thomas Kipps, MD, PhD Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting
Combination Therapy for CLL: What Evidence Do We Have?
Host: William Wierda, MD, PhD Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisti
MRD Testing to Guide Treatment Considerations in CLL
Host: Talha Munir, PhD Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting como
Combination Therapy in CLL: Identifying the Right Patient for the Right Treatment Approach
Host: Thomas Kipps, MD, PhD Host: William Wierda, MD, PhD Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, p
Visit Podcast Website
RSS Podcast Feed
Subscribe
Share
Add to MyCast